#35 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
This article highlights the need for rigorous outcome data on medical cannabis in psychiatry, which is critical as clinicians increasingly encounter patients using cannabis for mental health conditions without clear evidence-based guidance. Improved data collection and reporting standards, as demonstrated by oncology trials at ASCO, could help psychiatrists make informed recommendations, assess efficacy, and identify which patient populations benefit versus those at risk for adverse effects. For patients, better clinical evidence would enable shared decision-making about cannabis use and integration with conventional psychiatric treatments.
# Clinical Summary This article highlights emerging clinical trial data from major pharmaceutical companies on multiple myeloma treatments presented at ASCO, while also noting that psychiatry lacks adequate patient outcome data regarding medical cannabis use in this population. The piece underscores a critical gap in evidence generation for cannabis as a therapeutic option compared to the more robust clinical trial infrastructure supporting conventional oncology drugs. For clinicians managing patients with multiple myeloma or psychiatric comorbidities, this disparity means that evidence-based guidance on cannabis use remains limited despite growing patient interest and variable state-level legalization. The article emphasizes that structured outcome measurement and rigorous clinical research are essential to understand cannabis safety and efficacy profiles in complex patient populations. Clinicians should be aware that while conventional cancer therapeutics undergo standardized trials with measurable endpoints, cannabis therapies currently lack comparable evidence generation frameworks, limiting their ability to make evidence-based recommendations to patients seeking alternative or adjunctive treatments.
“What we’re seeing across oncology is that symptom management during treatment matters as much as the chemotherapy itself, and cannabis can play a legitimate role in controlling nausea, pain, and appetite loss in myeloma patients, but we need the same rigorous outcome tracking that we demand of our pharmaceuticals before we can confidently recommend it alongside conventional therapy.”
? While this headline primarily highlights oncology advances at ASCO, the mention of cannabis and patient outcome data underscores a broader clinical gap relevant to oncology and supportive care teams. Patients with multiple myeloma frequently experience chemotherapy-related neuropathy, nausea, and pain, symptoms for which some seek cannabis despite limited high-quality evidence in this population. The lack of standardized outcome measures and rigorous data collection around cannabis use in cancer patients makes it difficult for clinicians to counsel patients effectively or integrate cannabis into supportive care protocols. Healthcare providers managing myeloma should remain aware that patients may use cannabis concurrently with their cancer therapies, which carries potential drug interaction risks and may affect medication adherence or symptom assessment. Until better-designed trials and outcome registries are established in oncology populations, clinicians are advised to routinely ask about cannabis use, document it in the medical record, and discuss both potential symptom
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
